The Effect of Halofenate or Halofenate Free Acid on Human, Rat and Guinea Pig Platelet Aggregation

Summary

Halofenate free acid (HFA), the major metabolite of the hypolipemic agent halofenate, blocked the secondary phase of human platelet aggregation induced by ADP, epinephrine, or thrombin; higher concentrations of clohbrate free acid (CFA) were required to produce similar inhibitory effects on platelet aggregation. HFA and CFA inhibited collagen-induced aggregation of human, rat, or guinea pig platelets. Halofenate orally administered to rats caused inhibition of collagen-induced aggregation when plasma levels of HFA exceeded 300 μg/ml, a clinically achievable human plasma concentration. The platelet inhibitory effects of clofibrate administration were less than those observed with halofenate administration.

• References

• 1 Bluhm G. B, Riddle J. M. 1973 Seminars in Arthritis and Rheumatism. 2, 355.
• 2 Born G. V. R. 1962; Quantitative investigations into the aggregation of blood platelets. Journal of Physiology 162: 67 P.
• 3 Fanelli G. M, Bohn D. L, Reilly S. S, Baer J. E. 1972; Renal excretion and uricosuric properties of halofenate, a hypolipidemicuricosuric agent, in the chimpanzee. Journal of Pharmacology and Experimental Therapeutics 180: 377.
• 4 Gilfillan J. L, Hunt V. M, Huff J. W. 1971; The hypolipemic properties of 2-acetoamidoethyl (p-chlorophenyl)(m-trifluoromethylphenoxy)acetate in the rat (35474). Proceedings of the Society of Experimental Biology and Medicine 136: 1274.
• 5 Hucker H. B, Grady L. T, Michniewicz B. M, Stauffer S. C, White S. E, Maha G. E, McMahon F. G. 1971; Metabolism of a new hypolipidemic agent, 2-acetomidoethyl(p-chloro-phenyl)(m-trifluoromethylphenoxy)-acetate (halofenate) in the rat, dog, Rhesus monkey and man. Journal of Pharmacology and Experimental Therapeutics 179: 359.
• 6 Hutchison J. C, Wilkinson W. H. 1973; The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia. Atherosclerosis 18: 353.
• 7 Sirtori C, Hurwitz A, Sabih K, Azarnoff D. L. 1972; Clinical evaluation of MK-185: a new hypolipidemic drug. Lipids 7: 96.